Bleeding and clot risks after leaving the emergency department
Part of Blood & lymphatic clinical trials.
This study looks at people who take blood thinners and are sent home from the emergency department. It tracks whether they have bleeding or blood clot problems afterward, to improve safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are taking a blood thinner medicine, such as warfarin, enoxaparin, dabigatran, rivaroxaban, apixaban, or edoxaban.
- You were discharged from an emergency department or acute care unit with a prescription for this blood thinner.
- You are part of the Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG) healthcare area.
- You were not discharged from an outpatient clinic, home hospitalization, intermediate care, or residential facility.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at side effects of blood thinners (anticoagulants) in patients who visited the emergency department. It helps doctors understand how to better manage these medications.
This study looks at how to safely restart blood thinners after a major gastrointestinal bleed, specifically for people with atrial fibrillation or blood clots. It aims to find the best timing and approach to prevent future strokes or clots while avoiding another bleed.
This study tests whether taking a blood thinner after a stroke is safe and helpful for people who have atrial fibrillation (an irregular heartbeat) and have had a bleeding stroke in the past. It aims to prevent future strokes while managing the risk of another brain bleed.
This study tests a personalized approach to prevent blood clots in patients who have had surgery to repair blocked arteries in their legs. Researchers want to find the best blood-thinning medication for each individual to reduce serious complications while keeping you safe.
This trial compares two blood-thinning strategies after leg artery surgery or angioplasty to prevent dangerous blood clots. Participants will receive either rivaroxaban plus aspirin or aspirin alone, and researchers will monitor for clots over 30 days.
This trial tests a computerized tool that helps doctors decide who needs prevention medicines to lower the risk of blood clots after a hospital stay. It may help reduce preventable clotting risk for people who are less mobile and have added risk factors.
Hear when a new Acute Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.